Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 18/20 | 0.61 |
| ▸ | ITGA4 | P13612 | 18/20 | 0.61 |
| ▸ | ITGB7 | P26010 | 17/20 | 0.61 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.54 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.54 |
| ▸ | ITGAL | P20701 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7415773 | 0.93 | ITGB1 (0.52) | ITGB1ITGA4ITGB7ITGA2L3MBTL1 | |
| SCHEMBL5010881 | 0.88 | ITGB1 (0.66) | ITGB1ITGA4ITGB7ITGA2ITGB2 | |
| SCHEMBL5009922 | 0.84 | ITGB1 (0.69) | ITGB1ITGA4ITGB7ITGA2 | |
| SCHEMBL7424543 | 0.81 | L3MBTL1 (0.82) | ITGB1ITGA4ITGB7ITGA2L3MBTL1 | |
| SCHEMBL7417736 | 0.80 | ITGB1 (0.54) | ITGB1ITGA4ITGB7ITGA2ITGB2 | |
| SCHEMBL7417126 | 0.77 | ITGB1 (0.57) | ITGB1ITGA4ITGB7 | |
| SCHEMBL4886949 | 0.76 | ITGA4 (1.00) | ITGB1ITGA4ITGB7ITGA2 | |
| SCHEMBL7418253 | 0.75 | ITGB1 (0.57) | ITGB1ITGA4ITGB7ITGA2 | |
| SCHEMBL18589274 | 0.75 | ITGB1 (1.00) | ITGB1ITGA4ITGB7 | |
| SCHEMBL5160282 | 0.75 | ITGB1 (1.00) | ITGB1ITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1244625-A1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-02 | — | — | EP | claimed |
| WO-2001042215-A1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-14 | — | — | WO | claimed |
| EP-2007392-A2 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4 INHIBITORY COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007100763-A2 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4 INHIBITORY COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| EP-1244625-A1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-02 | — | — | EP | disclosed |
| US-20020133015-A1 | 4-pyridinyl-N-acyl-L-phenylalanines | KAPLAN GERALD LEWIS (US) | 2002-09-19 | — | — | US | disclosed |
| WO-2001042215-A1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133015-A1 | 4-pyridinyl-N-acyl-L-phenylalanines | VCAM1, ICAM1, SELPLG | ITGB1 13/4885ITGA4 8/4885ITGB7 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.